Terms: = Lung cancer AND H3F3B, H3_3A, 3021, ENSG00000132475, P84243, H3_3B, MGC87783, MGC87782, H3F3 AND Treatment
4 results:
1. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.
Cao GZ; Ma LY; Zhang ZH; Wang XL; Hua JH; Zhang JH; Lv Y; Zhang SB; Ou J; Lin WC
Acta Pharmacol Sin; 2023 Apr; 44(4):841-852. PubMed ID: 36253561
[TBL] [Abstract] [Full Text] [Related]
2. Clinical research on therapeutic effect of combined application of lobaplatin and irinotecan in treating recurrant small cell lung cancer.
Zhang H; Zhang Y; Wang C; Fang S; Xu B; Wang C; Wu J; Liu D
Pak J Pharm Sci; 2018 Sep; 31(5(Special)):2295-2298. PubMed ID: 30463828
[TBL] [Abstract] [Full Text] [Related]
3. Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell lung cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial.
Yang XB; Chai XS; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Xiao SJ
Chin J Integr Med; 2018 Oct; 24(10):734-740. PubMed ID: 28795387
[TBL] [Abstract] [Full Text] [Related]
4. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin.
Tang N; Du G; Wang N; Liu C; Hang H; Liang W
J Natl Cancer Inst; 2007 Jul; 99(13):1004-15. PubMed ID: 17596572
[TBL] [Abstract] [Full Text] [Related]
